Cargando…
晚期EGFR阳性NSCLC患者PD-L1表达特点及其与EGFR-TKIs治疗疗效关系的真实世界研究
Background and objective Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) is the first choice for first-line treatment of advanced patients with EGFR positive non-small cell lung cancer (NSCLC). For advanced NSCLC patients with negative drive gene and positive programmed cell...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Editorial board of Chinese Journal of Lung Cancer
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106801/ https://www.ncbi.nlm.nih.gov/pubmed/37035884 http://dx.doi.org/10.3779/j.issn.1009-3419.2023.101.09 |